Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 63

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9

Chee, Jacqueline L.Y., Saidin, Suzan, Lane, David P., Leong, Sai Mun, Noll, Jacqueline E., Neilsen, Paul M., Phua, Yi Ting, Gabra, Hani, Lim, Tit Meng · 2013 · Cell Cycle

Abstract

The p53 gene has been implicated in many cancers due to its frequent mutations as well as mutations in other genes whose proteins directly affect p53's functions. In addition, high expression of p53 [wild-type (WT) or mutant] has been found in the cytoplasm of many tumor cells, and studies have associated these observations with more aggressive tumors and poor prognosis. Cytoplasmic mis-localization of p53 subsequently reduced its transcriptional activity and this loss-of-function (LOF) was used to explain the lack of response to chemotherapeutic agents. However, this hypothesis seemed inadequate in explaining the apparent selection for tumor cells with high levels of p53 protein, a phenomenon that suggests a gain-of-function (GOF) of these mis-localized p53 proteins. In this study, we explored whether the direct involvement of p53 in the apoptotic response is via regulation of the caspase pathway in the cytoplasm. We demonstrate that p53, when present at high levels in the cytoplasm, has an inhibitory effect on caspase-9. Concurrently, knockdown of endogenous p53 caused an increase in the activity of caspase-9. p53 was found to interact with the p35 fragment of caspase-9, and this interaction inhibits the caspase-9 activity. In a p53-null background, the high-level expression of both exogenous WT and mutant p53 increased the resistance of these cells to cisplatin, and the data showed a correlation between high p53 expression and caspase-9 inhibition. These results suggest the inhibition of caspase-9 as a potential mechanism in evading apoptosis in tumors with high-level p53 expression that is cytoplasmically localized.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4161/cc.23054

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 54

  1. 10.1016/0092-8674(79)90293-9 · DOI · Paper page
  2. Kress M, 1979, J Virol, 31, 472, 10.1128/JVI.31.2.472-483.1979 · DOI · Paper page
  3. 10.1016/0042-6822(79)90250-2 · DOI · Paper page
  4. 10.1016/0092-8674(79)90053-9 · DOI
  5. 10.1038/278261a0 · DOI · Paper page
  6. Crook T, 1992, EMBO J, 11, 3935, 10.1002/j.1460-2075.1992.tb05487.x · DOI
  7. 10.1093/jnci/85.3.200 · DOI · Paper page
  8. 10.1002/1097-0142(19950315)75:6<1327::AID-CNCR2820750615>3.0.CO;2-P · DOI
  9. 10.1002/path.2784 · DOI · Paper page
  10. 10.1073/pnas.122062299 · DOI · Paper page
  11. Thukral SK, 1994, Mol Cell Biol, 14, 8315, 10.1128/MCB.14.12.8315 · DOI
  12. 10.1093/jnci/89.20.1530 · DOI
  13. Bosari S, 1995, Am J Pathol, 147, 790
  14. 10.1073/pnas.89.15.7262 · DOI · Paper page
  15. 10.1073/pnas.92.10.4407 · DOI · Paper page
  16. 10.1016/0959-8049(94)90082-5 · DOI
  17. 10.1016/0140-6736(92)92558-W · DOI · Paper page
  18. 10.1111/j.1600-0463.2008.00917.x · DOI
  19. Ghavam-Nasiri MR, 2007, Arch Iran Med, 10, 38
  20. Guillou L, 1996, Am J Pathol, 149, 1221
  21. 10.4161/cc.7.19.6751 · DOI · Paper page
  22. 10.1038/nchembio.546 · DOI · Paper page
  23. 10.1016/j.ccr.2011.06.004 · DOI · Paper page
  24. Martynova E, 2012, Oncotarget, 3, 132, 10.18632/oncotarget.447 · DOI
  25. 10.4161/cbt.11.8.14906 · DOI · Paper page
  26. 10.1146/annurev.biochem.68.1.383 · DOI · Paper page
  27. 10.1038/sj.cdd.4400536 · DOI · Paper page
  28. 10.1038/bjc.1992.273 · DOI · Paper page
  29. 10.1073/pnas.132241599 · DOI · Paper page
  30. 10.1158/1535-7163.MCT-06-0336 · DOI · Paper page
  31. Wei MC, 2000, Genes Dev, 14, 2060, 10.1101/gad.14.16.2060 · DOI · Paper page
  32. 10.1074/jbc.M003670200 · DOI · Paper page
  33. 10.1016/S1097-2765(03)00054-6 · DOI · Paper page
  34. 10.1038/40901 · DOI · Paper page
  35. 10.1038/35065125 · DOI · Paper page
  36. 10.1016/S1097-2765(00)80095-7 · DOI · Paper page
  37. 10.1084/jem.187.4.587 · DOI · Paper page
  38. 10.1038/sj.cdd.4401065 · DOI · Paper page
  39. 10.1074/jbc.273.42.27084 · DOI · Paper page
  40. 10.1073/pnas.0712034105 · DOI
  41. 10.4161/cc.10.1.14365 · DOI
  42. 10.1182/blood-2009-12-256149 · DOI
  43. 10.1016/S0092-8674(00)00073-8 · DOI · Paper page
  44. Stenger JE, 1994, EMBO J, 13, 6011, 10.1002/j.1460-2075.1994.tb06947.x · DOI · Paper page
  45. 10.1038/387299a0 · DOI · Paper page
  46. 10.1099/0022-1317-36-1-59 · DOI · Paper page
  47. König C, 1999, J Virol, 73, 2253, 10.1128/JVI.73.3.2253-2262.1999 · doi:10.1128/jvi.73.3.2253-2262.1999
  48. Blair Zajdel ME, 1988, Oncogene, 2, 579
  49. 10.1016/S1097-2765(03)00050-9 · DOI · Paper page
  50. 10.1016/S0092-8674(00)80434-1 · DOI · Paper page
  51. 10.4161/cc.11.5.19447 · doi:10.4161/cc.11.5.19447
  52. Blagosklonny MV, 2012, Oncotarget, 3, 601, 10.18632/oncotarget.548 · DOI
  53. 10.1016/S0301-4622(02)00011-X · DOI
  54. 10.1158/1078-0432.CCR-10-1587 · DOI · Paper page

Cited by

See all 63

Metadata

Authors
Chee, J. L. Y., Saidin, S., Lane, D. P., Leong, S. M., Noll, J. E., Neilsen, P. M., Phua, Y. T., Gabra, H., & Lim, T. M.
Venue
Cell Cycle
Published
2013-01-15
Volume
12
Issue
2
Pages
278-288
ISSN
  • 1538-4101
  • 1551-4005
Cited by
63
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.